{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:46:42Z","timestamp":1790192802110,"version":"4.1.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T00:00:00Z","timestamp":1468108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare entity with no standard of care and high mortality, despite the use of plasma exchange.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using specific search terms, all cases having TA-TMA treated with eculizumab and indexed in MEDLINE (English language only) by November 2014 were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 26 cases, 53% men, had a median age of 33 years (range 2-61). Transplant-associated thrombotic microangiopathy occurred after stem-cell transplant (35%) or solid-organ transplant (65%), frequently associated with the use of cyclosporine or tacrolimus (96%). A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13) level was always &gt;10%. After TA-TMA diagnosis, the following drug adjustments were made: discontinuation of cyclosporine or tacrolimus in 45%, dose reduction in another 27%, continuation of the drugs in 23%, and switch from cyclosporine to tacrolimus in remaining 5%. Plasma exchange was performed in \u223c43%. The median interval between transplant and initiation of eculizumab was 63 days (range 11-512). A median of 5.5 doses (range 2-21) of eculizumab was utilized with 92% response occurring after a median of 2 doses (range 1-18). At a median follow-up of 52 weeks (range 3-113), the survivors (92%) were doing well.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Within the limits of this retrospective analysis, our study demonstrates that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and plasma exchange.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1076029615599439","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T20:29:03Z","timestamp":1439238543000},"page":"175-180","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":58,"title":["Eculizumab in Transplant-Associated Thrombotic Microangiopathy"],"prefix":"10.1177","volume":"23","author":[{"given":"Prajwal","family":"Dhakal","sequence":"first","affiliation":[{"name":"Department of Medicine, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Giri","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Pathak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Reading Health System, West Reading, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,10]]},"reference":[{"issue":"9","key":"bibr1-1076029615599439","first-page":"565","volume":"12","author":"Chapin J","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"bibr2-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f24e8d"},{"key":"bibr3-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-0502(02)00020-4"},{"key":"bibr4-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-321315"},{"key":"bibr5-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705160"},{"key":"bibr6-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501445"},{"key":"bibr7-1076029615599439","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969020-00004"},{"key":"bibr8-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.00700.x"},{"key":"bibr9-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12859"},{"issue":"9","key":"bibr10-1076029615599439","first-page":"153","volume":"24","author":"Barnett ANR","year":"2011","journal-title":"Transplant Int"},{"key":"bibr11-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12319"},{"key":"bibr12-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.02.064"},{"key":"bibr13-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182a7fccd"},{"key":"bibr14-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03696.x"},{"key":"bibr15-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.565"},{"key":"bibr16-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.1078.1078"},{"key":"bibr17-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.97"},{"key":"bibr18-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12202"},{"key":"bibr19-1076029615599439","doi-asserted-by":"publisher","DOI":"10.5414\/CN108163"},{"key":"bibr20-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318230c0bd"},{"key":"bibr21-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981"},{"key":"bibr22-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03926.x"},{"key":"bibr23-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02159.x"},{"key":"bibr24-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0808527"},{"key":"bibr25-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829807aa"},{"key":"bibr26-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.497"},{"key":"bibr27-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648"},{"key":"bibr28-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705976"},{"key":"bibr29-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.06.013"},{"key":"bibr30-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.233"},{"key":"bibr31-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.03.004"},{"key":"bibr32-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1376153"},{"key":"bibr33-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.09.001"},{"key":"bibr34-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06588.x"},{"key":"bibr35-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.25"},{"issue":"1292","key":"bibr36-1076029615599439","first-page":"72","volume":"122","author":"Marr H","year":"2009","journal-title":"N Z Med J"},{"key":"bibr37-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.242"},{"key":"bibr38-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2010.01408.x"},{"key":"bibr39-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705657"},{"key":"bibr40-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2011.00978.x"},{"key":"bibr41-1076029615599439","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.04.007"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029615599439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1076029615599439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029615599439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:52Z","timestamp":1777385152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029615599439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,10]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1177\/1076029615599439"],"URL":"https:\/\/doi.org\/10.1177\/1076029615599439","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,10]]}}}